Studies are already underway
A new Omicron vaccine expected for September
05/05/2022, 8:13 p.m.
The Omikron vaccine should be on the market at the end of September at the latest. As announced by the European Medicines Agency, the necessary studies are already underway. In particular, the focus would be on adapting existing vaccines from Moderna and Biontech.
According to the European Medicines Agency (EMA), vaccines against the highly contagious omicron variant of the coronavirus could be approved by the end of September at the latest. The biggest opportunities lie in appropriately tailored mRNA vaccines from Moderna and Biontech, said Marco Cavaleri, director of vaccine strategy at EMA. The necessary clinical studies are in progress.
The EMA also reviews preparations from other manufacturers. However, it’s “no secret” that adaptations of mRNA vaccines from Moderna and Biontech to Omikron are already quite advanced. He did not give details of the study data collected so far.
At the same time, Cavaleri called on unvaccinated people to protect themselves against corona by getting vaccinated before autumn and winter. “The top priority must be to close the vaccination gap.” Only 50% of Europeans have been fully vaccinated and boosted to date, while 15% of Europeans over the age of 18 have yet to receive a single Covid-19 vaccine.